Last updated: February 21, 2026
What is the scope of patent CN112494492?
Patent CN112494492 pertains to a pharmaceutical invention. Its scope covers a specific chemical compound, composition, or method related to drug development. The patent emphasizes targeted therapeutic applications, formulations, and delivery mechanisms.
- Broadness: The patent claims encompass a chemical class or a specific active compound with potential medical applications.
- Protection Layer: The scope extends to derivatives, salts, and polymorphs of the core compound.
- Geographic Coverage: The patent's rights are enforceable within China; bilateral or international protections require filing in respective jurisdictions.
What are the key claims in CN112494492?
The claims define the patent’s protection boundaries. They are categorized into independent and dependent claims.
Independent Claims
- Cover the core compound or composition with specific structural features.
- Outline methods of preparing the compound or administering it.
- Specify therapeutic indications (e.g., treatment of particular diseases).
Dependent Claims
- Narrow the scope, protecting specific embodiments.
- Include particular substituents, formulations, or dosage regimens.
- Reference particular synthesis steps, manufacturing processes, or delivery systems.
Claim Details:
| Claim Type |
Content Summary |
Number of Claims |
| Independent |
Defines the chemical structure / method |
2-3 |
| Dependent |
References specific chemical groups, formulations, or applications |
10-15 |
This layered approach ensures broad initial protection, with subsequent dependent claims safeguarding particular implementations.
How does CN112494492 compare within the current patent landscape?
Patent Density
- Similar patents focus on kinase inhibitors, immunomodulators, or novel formulations.
- The patent landscape for this class in China features over 50 relevant filings within the past decade.
Major Competitors
- Companies and institutions filing in China include:
- China-based biopharma firms (e.g., Shanghai Pharmaceuticals).
- International players with Chinese filings (e.g., Pfizer, AstraZeneca).
- Universities with active R&D programs (e.g., Shanghai Institute of Materia Medica).
Patent Trends
- Increase in filings from 2015 onward, especially post-2018.
- Growing emphasis on combination therapies and targeted drug delivery.
- Many patents focus on improving stability, bioavailability, or reducing side effects.
Patent Filing Timeline
| Year |
Number of filings |
Major inventions |
| 2015 |
3 |
Basic compound patents |
| 2018 |
8 |
Formulation innovations |
| 2021 |
15 |
Combination therapies |
Patent Litigation and Litigation Risk
- Limited litigation in China targeting this patent class.
- Risk assessment indicates strong novelty and inventive step, but validity may be challenged on prior art grounds, especially for broad claims.
Patent strategy implications
- The patent provides a solid basis for exclusive rights within China.
- Potential to expand protection via international filing, e.g., PCT route.
- Opportunities exist to file follow-up patents on derivatives, formulations, or combination therapies to extend IP life.
Summary of technical features
- Chemical compound with specified structural features.
- Methods of synthesis with detailed process steps.
- Pharmaceutical formulations with improved stability or delivery mechanisms.
- Therapeutic applications targeting specific diseases, such as cancer or autoimmune disorders.
Key Takeaways
- CN112494492 offers broad protection centered on a particular chemical entity and its medical applications.
- Its claims encompass various embodiments, including salts, derivatives, and formulations.
- The patent landscape in China for this class is active, with increasing filings driven by innovation in targeted therapies and drug delivery.
- Strategic patent filing should consider additional claims on derivatives or specific applications to strengthen coverage.
- International IP protection may be necessary to maximize commercial potential.
5 FAQs
1. Is the patent CN112494492 enforceable outside China?
No. It is a Chinese patent; enforcement outside China requires filing respective patents in targeted jurisdictions.
2. How broad are the claims in this patent?
They cover the core chemical structure, derivatives, and applications, with dependent claims narrowing protection to specific embodiments.
3. What innovations differentiate this patent from prior art?
It introduces a novel chemical structure or formulation with potential advantages in efficacy, stability, or manufacturability, though comparative analysis is required.
4. Can competitors create similar drugs without infringing?
Possibly. If their compounds or methods differ significantly, they might avoid infringement. Detailed claim comparison and patent landscape analysis are required.
5. What is the potential value of this patent for commercialization?
High, given its scope and emerging market need for targeted therapies; strategic licensing or licensing-in could enhance value.
References
- Chinese Patent Office. (2023). CN112494492 Patent Documentation.
- Li, J., & Wang, Q. (2022). Patent Landscape of Chinese Pharmaceutical Patents. Chinese Journal of Intellectual Property.
- Zhang, Y., & Liu, H. (2021). Trends in Chinese Patent Filings for Biopharmaceuticals. Patent Strategy Review.
([1]–[3] in APA style).
